Vanda Pharmaceuticals FDA Approval Sparks Pre-Market Jump

15 days ago

Valerie Titel

"Vanda Pharmaceuticals is jumping in pre-market up 22%. Because it's gotten FDA approval for its drug in the prevention of motion induced sickness. It's actually the first drug to be approved for this sickness in over 40 years. So, there's going to be a new drug on the market in the coming months that perhaps can help you with sickness out at sea, maybe sickness in the car when you're driving to grandma's for New Year's Day as well. But um it essentially works by blocking a brain receptor that's linked to nausea and vomiting."

The speaker highlights that Vanda Pharmaceuticals is experiencing a 22% pre-market jump due to FDA approval for its novel drug aimed at preventing motion-induced sickness. This event marks the first such approval in over four decades, indicating a potentially significant market catalyst as the new drug is expected to launch in the coming months.

Related Stocks